Black et al. Treat to target in gout. Monthly rheumatologist review and urate titration vs 6-monthly. 89% vs 40% at target ≤0.30mmol/L (<5mg/dl). SU decrease 38% vs 18%. US features also improved. @RheumNow #ACR22 Abstr#1579 https://t.co/TvxWAtl83y

• The TICOG Study: Tight Control of Gout - A Randomized, Controlled Trial of Targ…

#ACR22 Abstr#2061 It's time to tight control newly diagnosed #lupus nephritis patients. In a cohort study which 16% developed advanced CKD, risk was reduced if remission achieved by 12 mths of diagnosis. =>1 flare & shorter time-on-therapy increased risk @RheumNow #ACRBest https://t.co/swYn2g4hqe

#SLE mortality in South Carolina Lupus Cohort Standardized mortality ratio (SMR) is higher in blacks Higher SLICC scores in blacks abst#2106 #ACR22 @rheumnow https://t.co/NAdNhUHsbc

Deane et al STOP RA trial. DBRCT HCQ vs PBO pre-RA. Treat 1 year, stop, 2 year follow up. Does not prevent RA development. Literally no effect at all, even during treatment phase. @RheumNow #ACR22 Abstr#1604 https://t.co/7jHv7cs5DT https://t.co/GNblKs90RU

• Hydroxychloroquine Does Not Prevent the Future Development of Rheumatoid Arthri…

Hoffmann-Vold. ILD in pSS. Frequently progressive - 21% FVC, 32% DLCO, 45% HRCT progression over 1 year. @RheumNow #ACR22 Abstr#2049 https://t.co/um3845jOFC https://t.co/64BEB2VyG0

• ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive - ACR …

New SLE Rx. Deucravitinib a TYK2i phase 2 RCT showed SRI4 endpoint. Subset of 3 mg bid was best vs 6 mg bid and 12 mg OD. Skin via CLASI-50 & other endpoints also positive. Awaiting phase III. Abst1117 #ACR22 @RheumNow https://t.co/fZI3AV5pML

Hidekawa et al. HCQ use assoc reduced severe infection in LUNA SLE registry, HR 0.26. ?due to better disease control rather than anti-infectious role, but HR 0.32 in multivariable model including SLEDAI. @RheumNow #ACR22 Abstr#2059 https://t.co/EgTJOAymoF https://t.co/gmchk9ZS5L

• Association of Hydroxychloroquine with the Incidence of Infectious Disease in S…

Is #Tofacitinib an option in #PMR poly myalgia rheumatica? RCT of Tofa 5 mg bid vs prednisone 15 mg/d and tapering. Equal results. Needs a phase 3 trial but could be an option if needing to avoid prednisone ex osteoporosis, DM, etc. abst#1107 #ACR22 @RheumNow https://t.co/OgcgslwaB5

⇧ brain functional connectivity to the insula between the mid-posterior IC & brain areas involved in sensory (thalamus), learning/affective (parahippocampal gyrus), cognitive (prefrontal cortex) pain modulation in PsA. Sunzini F Abs#2256 https://t.co/5TUcOacuIS #ACR22 @RheumNow https://t.co/7IqLYzzpyA

• MRI Spinal Lesions in Patients Without MRI or Radiographic Lesions in the Sacro…

Figueroa Parra @AliDuarteMD et al. Multimorbidity in SLE. Higher at classification - due to non-SLE assoc. SLE-assoc drive increased accumulation over time but non-SLE assoc also increased @RheumNow #ACR22 Abstr#2091 https://t.co/6IyhovSNYA https://t.co/qmYfoqCTtz

• Burden and Incidence of Multimorbidity in Systemic Lupus Erythematosus in a Com…

Kavanaugh et al. TYK2i deucravacitinib in PsA. Nice breakdown of MDA and its components over 16 weeks. MDA achieved 23-24% with deucravacitinib at 16 weeks vs 8% with placebo @RheumNow #ACR22 Abstr#2136 https://t.co/9IG8CeZzMh https://t.co/Vg8E20y7Z8

• Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in a Phase 2 T…

Rhee @RennieRhee et al. Combined cranial vessel wall and orbital MRI for GCA. Improves sensitivity 77% vs 69% with loss of specificity 91% vs 95%. Identifies abnormalities in some without visual symptoms - at risk of vision loss @RheumNow #ACR22 Abstr#1618 https://t.co/OtGm7sEWtU https://t.co/YM4WLahubH

• Combined Orbital and Cranial Vessel Wall MRI for Diagnosis and Longitudinal Mon…

#ACR22 Abstr#2055 SRI-4 and BICLA: how do they converge and diverge? Analyses of 6 x Non-Renal #Lupus RCT showed discordance (12-30%).When discordant, SRI-4 classified more pts as responders vs BICLA. Concordance higher at 52 vs 24 wks. Vital to interpret both outcomes @RheumNow https://t.co/prSfTrv0E8

Charlton et al PsA patients face longer diagnostic delay and less intensive treatment than RA patients for equivalent disease activity. @RheumNow #ACR22 Abstr#1613 https://t.co/HedK59QsKs https://t.co/xaJUy7w1t4

• Diagnostic Delay and Less Intensive Therapy for People with Psoriatic Arthritis…